Table 1 Biographical and oncological data
Item | Group A | Group B | Remarks | |
|---|---|---|---|---|
Mean age (years) | 57.1 | 54.6 | n.s. | |
Mean Karnofsky performance Index | 7.8 | 7.5 | n.s. | |
Follow-up (years) | 4.1 | 5.0 | p = 0.004 | |
T-stage | T1 | 14 (16%) | 20 (18%) | n.s. |
T2 | 33 (37%) | 49 (43%) | ||
T3 | 8 (9%) | 19 (16%) | ||
T4 | 35 (38%) | 26 (23%) | ||
N-stage | N0 | 20 (22%) | 46 (40%) | n.s. |
N1 | 23 (26%) | 24 (21%) | ||
N2 | 47 (52%) | 30 (26%) | ||
N3 | 0 | 14 (13%) | ||
UICC stage | I | 6 ( 7%) | 10 ( 9%) | n.s. |
II | 7 (8%) | 22 (19%) | ||
III | 19 (21%) | 26 (23%) | ||
IV | 58 (64%) | 56 (49%) | ||
Pre-treatment | None | 24 (27%) | 17 (15%) | p < 0.001 |
Surgery | 66 (73%) | 97 (85%) | ||
Total dose (Gy) | Conventional fractionation | N = 75 | N = 73 | p < 0.001 |
30Gy (1) | 2Gy (1) | |||
36Gy (1) | 8Gy (1) | |||
50Gy (7) | 36Gy (1) | |||
58Gy (2) | 44Gy (1) | |||
60Gy (32) | 56Gy (1) | |||
64Gy (9) | 60Gy (31) | |||
70Gy (23) | 62Gy (1) | |||
66Gy (1) | ||||
70Gy (31) | ||||
72Gy (2) | ||||
76Gy (1) | ||||
80Gy (1) | ||||
Total dose (Gy) | Hyperfractionation | N = 15 | N = 41 | |
55.8Gy (1) | 13.2Gy (1) | |||
70.8Gy (1) | 81.6Gy (2) | |||
72.0Gy (11) | 82.8Gy (35) | |||
72.8Gy (1) | 85.2Gy (1) | |||
76.8Gy (1) | 85.5Gy (1) | |||
87.8Gy (1) | ||||
Daily fraction | Conventional fractionation | 2.0 Gy (74) | 2.0Gy (73) | p = 0.0012 |
3.0 Gy (1) | ||||
Hyperfractionation | 1.2 Gy (14) | 1.2 Gy (41) | ||
1.4 Gy (1) | ||||
Simultaneous chemotherapy | 14 | 0 | p < 0.001 |